Circulating MicroRNA Biomarkers in Melanoma: Tools and Challenges in Personalised Medicine.
Circulating MicroRNA Biomarkers in Melanoma: Tools and Challenges in Personalised Medicine.
复制标题
DOI：
10.3390/biom8020021
复制
发表时间：
2018-04-26
期刊：
影响因子：
5.5
通讯作者：
Newbury SF
中科院分区：
文献类型：
--
作者：
Mumford SL;Towler BP;Pashler AL;Gilleard O;Martin Y;Newbury SF
黑色素瘤的有效治疗在很大程度上取决于早期诊断。当在早期非转移期检测到黑色素瘤时，手术切除几乎100%可治愈，然而当在晚期转移期III和IV期检测到黑色素瘤时，由于目前治疗方案的疗效有限，5年生存率分别下降到~50%和10-25%。这表明迫切需要确定能够检测复发和转移性疾病高风险患者的生物标志物，这将允许早期干预和生存获益。过去几十年积累的证据强调了循环分子生物标志物在黑色素瘤诊断和预后中的潜在应用，包括乳酸脱氢酶（LDH）、S100钙结合蛋白B （S100B）和循环肿瘤DNA （ctDNA）片段。自2010年以来，循环microRNAs （miRNAs）越来越被认为是黑色素瘤更强大的非侵入性生物标志物，因为它们在恶劣的血液条件和不同的样品处理和分离条件下具有结构稳定性。一些分析前和分析变量对血清样本或血浆样本之间相对miRNA水平的准确定量提出了挑战，导致黑色素瘤循环miRNA生物标志物的研究结果相互矛盾。在这篇综述中，我们对迄今为止发表的黑色素瘤循环miRNA生物标志物进行了综述。
Effective management of melanoma depends heavily on early diagnosis. When detected in early non-metastatic stages, melanoma is almost 100% curable by surgical resection, however when detected in late metastatic stages III and IV, 5-year survival rates drop to ~50% and 10–25%, respectively, due to limited efficacy of current treatment options. This presents a pressing need to identify biomarkers that can detect patients at high risk of recurrence and progression to metastatic disease, which will allow for early intervention and survival benefit. Accumulating evidence over the past few decades has highlighted the potential use of circulating molecular biomarkers for melanoma diagnosis and prognosis, including lactate dehydrogenase (LDH), S100 calcium-binding protein B (S100B) and circulating tumor DNA (ctDNA) fragments. Since 2010, circulating microRNAs (miRNAs) have been increasingly recognised as more robust non-invasive biomarkers for melanoma due to their structural stability under the harsh conditions of the blood and different conditions of sample processing and isolation. Several pre-analytical and analytical variables challenge the accurate quantification of relative miRNA levels between serum samples or plasma samples, leading to conflicting findings between studies on circulating miRNA biomarkers for melanoma. In this review, we provide a critical summary of the circulating miRNA biomarkers for melanoma published to date.
登录
查看更多内容
影响因子：
16
作者：
Crescitelli R;Lässer C;Szabó TG;Kittel A;Eldh M;Dianzani I;Buzás EI;Lötvall J
通讯作者：
Lötvall J
影响因子：
64.8
作者：
Chendrimada, TP;Gregory, RI;Shiekhattar, R
通讯作者：
Shiekhattar, R
影响因子：
--
作者：
Dias F;Teixeira AL;Ferreira M;Adem B;Bastos N;Vieira J;Fernandes M;Sequeira MI;Maurício J;Lobo F;Morais A;Oliveira J;Kok K;Medeiros R
通讯作者：
Medeiros R
影响因子：
--
作者：
Daniels, Sylvanne M.;Melendez-Pena, Carlos E.;Gatignol, Anne
通讯作者：
Gatignol, Anne
影响因子：
--
作者：
Fogli, Stefano;Polini, Beatrice;Nieri, Paola
通讯作者：
Nieri, Paola